Skip to main content

Table 2 Univariate analysis of pMT1-MMP expression in clinicopathologic features

From: Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression

Characteristics

N*

Mean intensity

Positive

N (%)

Negative

N (%)

P

Type of samples

     

   Normal control samples

56

0.34

19 (33.9)

37 (66.1)

 

   Tumor from primary site

289

0.72

187 (64.7)

102 (35.3)

0.0001

   Tumor from metastasis

103

0.72

76 (73.8)

27 (26.2)

0.5900

Age

     

   < 1 year

125

0.64

58 (46.4)

67 (53.6)

0.0002

   > 1 year

184

0.78

124 (67.4)

60 (32.6)

 

Clinical stage

     

   1

68

0.66

41 (60.3)

27 (39.7)

0.3700

   4

103

0.75

69 (67.0)

34 (33.0)

 

Specimen type

     

   Mass screening

55

0.31

24 (43.6)

31 (56.4)

0.0006

   Standard

234

0.8

160 (68.4)

74 (31.6)

 

MYCN oncogene

     

   Amplified

34

0.52

21 (61.8)

13 (38.2)

0.1000

   Not amplified

214

0.69

100 (46.7)

114 (53.3)

 
  1. *N: number of specimens